论文部分内容阅读
目的探讨吉非替尼治疗晚期非小细胞肺癌(NSCLC)的疗效与表皮生长因子受体(EGFR)基因突变的关系。方法选择36例Ⅲb期或Ⅳ期经铂类治疗方案无效的NSCLC患者,根据有无EGFR基因突变分为有EGFR基因突变组(A组,11例)与无EGFR基因突变组(B组,25例),均予以吉非替尼治疗,分析其疗效与EGFR基因突变的关系。结果 A组吉非替尼治疗有效率优于B组(81.8%vs.16.0%)(P<0.05)。结论 EGFR基因突变的检测可作为吉非替尼治疗NSCLC疗效的一个预测指标。
Objective To investigate the efficacy of gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) and the relationship between epidermal growth factor receptor (EGFR) gene mutation. Methods Thirty-six patients with stage Ⅲb or Ⅳ NSCLC who were not treated by platinum regimen were divided into two groups according to the presence or absence of EGFR gene mutations: EGFR gene mutation group (11 cases) and EGFR gene mutation group (B group, 25 Cases) were given gefitinib treatment, analysis of its efficacy and EGFR gene mutations. Results The efficacy of gefitinib in group A was better than that in group B (81.8% vs 16. 0%) (P <0.05). Conclusion The detection of EGFR gene mutations can be used as a predictor of the efficacy of gefitinib in the treatment of NSCLC.